Skip to main content

Schizophrenia

  • Chapter
  • First Online:
Psychiatric Drugs in Children and Adolescents

Abstract

Schizophrenia is characterized by positive, negative, cognitive and mood symptoms. Treatment includes both psychosocial and psychopharmacological interventions. A "primum non nocere" principle is recommended when choosing an antipsychotic for adolescents, who are more vulnerable to many side effects. Rationales for monitoring side effects and switching antipsychotics if needed should be considered. Despite lack of evidence in this age group, adolescents seem to benefit from cognitive behavioural therapy, family interventions and general principals of open dialogue as well as an orientation towards recovery as perceived by patients and parents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literature

  • American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn (DSM-5™). American Psychiatric Publishing, Washington/London

    Google Scholar 

  • Correll CU (2010) From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25:12–21

    Article  Google Scholar 

  • De Hert M, Detraux J, van Winkel R et al (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114–126

    Article  PubMed  Google Scholar 

  • Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU (2012) Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 11:527–542

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McClellan J, Stock S, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI) (2013) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 52:976–990

    Article  PubMed  Google Scholar 

  • Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E (2011) What we know and what we don’t know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol 21:680–690

    Article  CAS  PubMed  Google Scholar 

  • Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160(Suppl 17):54–59

    Google Scholar 

  • National Institute for Health and Clinical Excellence (2013a) Psychosis and schizophrenia in children and young people. Recognition and management. NICE clinical guideline 155 (http://www.nice.org.uk/cg155)

  • National Institute for Health and Clinical Excellence (2013b) Quality standard for self-harm. QS34 (http://publications.nice.org.uk/quality-standard-for-selfharm-qs34)

  • Sassim N, Grohmann R (1988) Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry 21:306–307

    Article  CAS  PubMed  Google Scholar 

  • Schimmelmann BG, Paulus S, Schacht M, Tilgner C, Schulte-Markwort M, Lambert M (2005) Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 15:249–258

    Article  PubMed  Google Scholar 

  • Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013a) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 26:219–230

    Article  PubMed  Google Scholar 

  • Schimmelmann BG, Walger P, Schultze-Lutter F (2013b) The significance of at-risk symptoms for psychosis in children and adolescents. Can J Psychiatry 58:32–40

    PubMed  Google Scholar 

  • World Health Organization (1996) Multiaxial classification of child and adolescent psychiatric disorders. The ICD – 10 classification of mental and behavioral disorders in children and adolescents. Cambridge University Press, Cambridge

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Benno G. Schimmelmann MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Wien

About this chapter

Cite this chapter

Schimmelmann, B.G., Mehler-Wex, C., Wewetzer, C. (2014). Schizophrenia. In: Gerlach, M., Warnke, A., Greenhill, L. (eds) Psychiatric Drugs in Children and Adolescents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1501-5_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1501-5_25

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1500-8

  • Online ISBN: 978-3-7091-1501-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics